Isolation of an Egg-Adapted Influenza A(H3N2) Virus without Amino Acid Substitutions at the Antigenic Sites of Its Hemagglutinin

Tomoko Kuwahara1, Emi Takashita1, Seiichiro Fujisaki1, Masayuki Shirakura1, Kazuya Nakamura1, Noriko Kishida1, Hitoshi Takahashi1, Noriko Suzuki2, Yoshihiro Kawaoka2,3,4, Shinji Watanabe1, and Takato Odagiri*

1Influenza Virus Research Center, National Institute of Infectious Diseases, Tokyo; 2Saitama Institute of Public Health, Saitama; 3Division of Virology, Department of Microbiology and Immunology; 4Department of Special Pathogens, International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Tokyo, Japan; and 5Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, WI, USA

SUMMARY: Antigenic changes in the hemagglutinin protein of recent A(H3N2) viruses often arise when these viruses adapt to their egg host. By serial egg passages of a cell-propagated virus, we successfully isolated an egg-adapted influenza A(H3N2) virus, A/Saitama/103/2014, without amino acid substitutions at the antigenic sites of its hemagglutinin protein but with multiple substitutions in its neuraminidase protein. Antigenic analysis of this egg-adapted A/Saitama/103/2014 virus indicated that its antigenicity did not differ from that of the World Health Organization prototype cell-propagated vaccine virus: A/Hong Kong/4801/2014. Our results suggest that this strategy may facilitate egg-based vaccine production without antigenic alterations in hemagglutinin by egg adaptation.

INTRODUCTION

Vaccination plays a key role in preventing infection and severe outcomes caused by influenza viruses. Most influenza vaccines are produced in embryonated chicken eggs; however, during egg adaptation of viruses, amino acid substitutions arise at the antigenic sites of the hemagglutinin (HA) protein (1–4), resulting in antigenic changes to the virus and decreased vaccine effectiveness. Recent studies indicate that the T160K or L194P substitution at an antigenic site of the HA of recent H3N2 viruses during egg passage significantly affects antigenicity and the induction of appropriate protective antibodies, thus pointing to an association with low vaccine effectiveness (5,6). Here, we successfully isolated an egg-adapted influenza A/Saitama/103/2014 virus with amino acid substitutions in its neuraminidase (NA) but no antigenic changes in its HA by inoculating the cell-grown virus into eggs. Because no significant antigenic changes occurred in the HA of this virus even after extensive passages (> 21), the World Health Organization (WHO) has listed this extensively egg-passaged virus as a candidate vaccine virus for the development and production of vaccines for use in the 2017–2018 northern hemisphere influenza season (7).

MATERIALS AND METHODS

Cells: MDCK cells were maintained in minimum essential medium supplemented with 10% heat-inactivated fetal calf serum. MDCK-SIAT1 cells, i.e., engineered MDCK cells with over-expressed α 2,6-linked sialic acid residues (8), were kindly provided by Dr. Matrosovich (Philips Univ., Marburg, Germany) and were maintained in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich, St. Louis, MO, USA) supplemented with 5% heat-inactivated fetal calf serum, a penicillin-streptomycin solution (Sigma-Aldrich), and 1 mg/mL genetin (Gibco, Grand Island, NY, USA). NIID-MDCK cells are established and authorized MDCK cells for cell-based vaccine production (9). NIID-MDCK cells were maintained in OptiPRO SFM (Gibco) supplemented with 2 mM L-glutamine. All the cell lines were cultured at 37°C and 5% CO2.

Viruses: All Japanese virus isolates used in this study were collected through the national influenza surveillance system of Japan without a formal ethical review. The cell-grown viruses were amplified in NIID-MDCK or MDCK-SIAT1 cells at 34°C for 48 h. The egg-grown viruses were propagated in the amniotic or allantoic cavities of 10-day-old embryonated chicken eggs at 35°C for 48 h.

Sequence analysis: Viral RNA was extracted from virus isolates by the QIAamp Viral RNA Kit (Qiagen, Hilden, Germany). Nucleotide sequences were determined by Sanger sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit and 3730 DNA Analyzer (Applied Biosystems, Foster City, CA, USA) or by deep sequencing with MiSeq Reagent Kits v2 on the MiSeq next-generation sequencer platform (Illumina, San Diego, CA, USA) (10). DNA sequences were assembled and analyzed with Sequencher ver. 4.9 software (Gene Codes, Ann Arbor, MI, USA) or were aligned in CLC Genomics Workbench 8 (CLC bio, Aarhus, Denmark). Primer sequences for the Sanger sequencing are available upon request. Sequences of the HA and NA genes that were obtained in this study were deposited in the EpiFlu database of the Global Initiative on Sharing Avian Influenza Data (GISAID). Accession numbers are shown in Table 1.
An enzyme-linked immunosorbent assay (ELISA)-based microneutralization assay: This assay was performed as described in the WHO manual (11) with a minor modification. Briefly, 100 TCID<sub>50</sub> (50% tissue culture infectious dose) of each virus was mixed with serially diluted post-infection ferret serum (2-fold dilution), which was pretreated with a receptor-destroying enzyme (RED II; Denka Seiken, Tokyo, Japan), and the mixture was incubated for 1 h at 37°C. After that, a suspension of MIDCK-SIAT1 cells (2 × 10<sup>5</sup> cells) was added into each well, and the plates were incubated at 35°C and 5% CO<sub>2</sub> for 18 to 20 h. Cells were then fixed with 80% acetone in phosphate buffered saline (PBS), and an ELISA was carried out to identify the wells positive for virus growth by means of a mixture of mouse anti-influenza A nucleoprotein monoclonal antibody clones A1 and A3 (1:15,000 dilution; Millipore, Bedford, MA, USA) as primary antibodies and a goat anti-mouse immunoglobulin G (IgG) antibody conjugated with horseradish peroxidase (1:2,000 dilution; Kirkegaard & Perry Laboratories [KPL], Gaithersburg, MD, USA) as a secondary antibody. The neutralization titer was determined as the reciprocal of the highest serum dilution as described in the WHO manual (11).

Cloning of viruses by limiting dilution: Viruses were serially diluted (dilution range: 10<sup>−3</sup>–10<sup>−7</sup>), and each dilution was inoculated into the amniotic cavities of 10-day-old embryonated chicken eggs. Eggs inoculated with the virus were incubated at 35°C for 48 h. Viruses from the highest dilution showing a hemagglutination with 0.5% chicken red blood cells were passaged and analyzed.

Table 1. Accession numbers of sequences of the HA and NA genes deposited in EpiFlu database

| Virus name | Passage history | HA_ID | NA_ID |
|------------|----------------|-------|-------|
| A/Saitama/103/2014 Clinical specimen | EP11022843 | EP11022844 |
| A/Saitama/103/2014 C3 | EP11105790 | EP11105791 |
| A/Saitama/103/2014 C3E4 | EP11105792 | EP11105793 |
| A/Saitama/103/2014 C3E8 | EP11105796 | EP11105797 |
| A/Saitama/103/2014 CEXP002 (C3E20E8/E1) | EP11105794 | EP11105795 |

Table 2. Amino acid substitutions in egg-adapted influenza A/Saitama/103/2014 (H3N2)

| Passage history | HA | NA |
|-----------------|----|----|
| 160 225 435     |    |    |
| 143 148 150     |    |    |
| 329 331 335     |    |    |
| 347 358 367 369 |    |    |
| 437             |    |    |

A(H3N2) Virus without Antigenic Changes in Eggs

RESULTS

Isolation of the egg-adapted influenza A(H3N2) virus: The influenza A/Saitama/103/2014 (Saitama) virus was initially isolated from a clinical sample, which was collected through the national influenza surveillance system of Japan and was passaged twice in NIID-MDCK cells (and was designated as strain C3). Because we did not have a sufficient amount of the clinical sample to inoculate both NIID-MDCK cells and eggs for virus isolation, we prioritized inoculation of the sample into NIID-MDCK cells to secure the A/Saitama/103/2014 virus. To obtain egg-adapted viruses, the NIID-MDCK cell-propagated C3 virus was serially passaged in the amniotic cavities and then in the allantoic cavities of 10-day-old embryonated chicken eggs. The virus grew well in the amniotic cavities even at the first passage, with a high hemagglutination titer when 1% guinea pig red blood cells were used (> 1:256). However, for full adaptation in eggs, which means that hemagglutination activity was detected in all eggs that we used for virus passaging, the virus needed 4 further passages in the amniotic cavities (designated as C3E4) and 4 passages in the allantoic cavities (designated as C3E8).

We then compared the amino acid sequences of the HA and NA proteins of this series of Saitama viruses with those of the virus in a clinical sample from which the Saitama virus was originally isolated (Table 2). To this end, nucleotide sequence analyses were conducted by Sanger sequencing or by deep sequencing. After nucleotide sequence analyses, we found that the cell-propagated C3 virus had no amino acid substitutions in its HA but had acquired the T148I substitution in its NA (Table 2). The NA T148I substitution is associated with virus adaptation to cell culture and may confer a receptor-binding property to NA (12,13). The C3E4 virus, which replicated well in the amniotic cavities, acquired an additional substitution, T153N, in its NA. The egg-adapted C3E8 virus acquired the HA H435L substitution, which is located in the stem region of HA, and 8 substitutions (R150H, S235G, T369K) in addition to substitutions T148I and T153N in its NA (Table 2). The NA T148I substitution is associated with virus adaptation to cell culture and may confer a receptor-binding property to NA (12,13). The C3E4 virus, which replicated well in the amniotic cavities, acquired an additional substitution, T153N, in its NA. The egg-adapted C3E8 virus acquired the HA H435L substitution, which is located in the stem region of HA, and 8 substitutions (R150H, S235G, T369K) in addition to substitutions T148I and T153N in its NA (Table 2).

Virus neutralization by antiserum against the egg-
adapted influenza A(H3N2) virus: Given that the egg-adapted Saitama (C3E8) virus possessed a single substitution, H435L, in the stem region of HA, we performed an ELISA-based microneutralization (MN) assay to assess the antigenicity of the egg-adapted Saitama virus using post-infection ferret antisera against the Saitama and A/Hong Kong/4801/2014 (Hong Kong) viruses, the latter being an A(H3N2) prototype vaccine strain for the 2017–2018 northern hemisphere influenza season. As shown in Table 3, ferret antisera against the cell-propagated Saitama and Hong Kong viruses effectively inhibited the Saitama (C3E8) virus, suggesting that the antigenicity of the egg-adapted Saitama virus was retained even after egg adaptation and that the Saitama (C3E8) virus was antigenically a Hong Kong-like virus. We also found that the HA H435L substitution did not affect the antigenicity of the Saitama (C3E8) virus.

We then examined the virus-neutralizing activity of the antiserum, raised against the egg-adapted Saitama (C3E8) virus toward recently circulating H3N2 viruses (Table 3) by the MN assay. Replication of all the circulating viruses tested was effectively inhibited by the antiserum against the Saitama (C3E8) virus as well as the cell-propagated Saitama and Hong Kong viruses with a ≤ 4-fold reduction in MN titers as compared with the homologous virus titers. Nevertheless, most of the viruses tested were poorly inhibited by the antiserum against the egg-propagated Hong Kong virus with a ≥ 8-fold reduction in MN titers as compared with the homologous virus titer. This is because the egg-propagated Hong Kong virus possesses egg-adaptive mutations in the head region of its HA (N96S, T160K, and L194P). Our findings thus suggest that the antiserum against the egg-adapted Saitama (C3E8) virus will show better coverage against currently circulating viruses than will the antiserum against the egg-propagated Hong Kong virus.

Antigenicity of the cloned egg-adapted influenza A(H3N2) virus: Because 8 NA substitutions in the Saitama (C3E8) virus were represented in the mixed population (Table 2), we attempted to isolate clones by limiting dilution. After 2 limiting-dilution passages in allantoic cavities, we obtained 2 clones: C3E8-m2 and C3E8-m7. These clones possessed 2 (N329T and T369K) or 7 substitutions (V143E, R150H, S331G, S335G, H347R, N358G, and N367D) besides the T148I and T153N substitutions in their HA (Table 2). The non-homologous HA amino acid changes found in C3E8-m7 may affect C3E8-m7 neutralization by antisera against Hong Kong viruses.

The C3E8 virus was further passaged in eggs (> 13) in our laboratory and then passaged (8 times) at the Center for Biologics Evaluation and Research in the USA, and ultimately yielded the A/Saitama/103/2014 (CEXP002)

---

Table 3. Virus neutralization by antiserum against egg-adapted influenza A/Saitama/103/2014 (H3N2)

| Virus Passsage history | Microneutralization titer using post-infection ferret antisera against: |
|-----------------------|------------------------------------------------------------------------|
|                       | A/Saitama/103/2014 | A/Hong Kong/4801/2014 |
|                       | Cell | C3E8 | Cell | Egg |
| A/Saitama/103/2014 C2 | 1,280 | 1,280 | 1,280 | 1,280 | 640 |
| A/Saitama/103/2014 C3E8 | 1,280 | 1,280 | 1,280 | 1,280 | 160 |
| A/Hong Kong/4801/2014 C6 | 1,280 | 1,280 | 1,280 | 1,280 | 640 |
| A/Hong Kong/4801/2014 E8 | 1,280 | 1,280 | 1,280 | 1,280 | 2,560 |
| A/Amori/13/2016 C2 | 1,280 | 2,560 | 1,280 | 640 |
| A/Kawasaki/109/2016 C2 | 1,280 | 1,280 | 640 | 320 |
| A/Gifu/31/2016 C2 | 640 | 1,280 | 640 | 640 |
| A/Shimane/50/2016 C2 | 640 | 1,280 | 1,280 | 640 |
| A/Kanagawa/AC1602/2016 C1 | 320 | 1,280 | 320 | 80 |
| A/Mie/27/2016 C3 | 320 | 1,280 | 320 | 20 |
| A/Yokohama/124/2016 C4 | 640 | 640 | 320 | 160 |
| A/Sapporo/89/2016 C3 | 320 | 640 | 320 | 160 |
| A/Niigata-C/53/2016 C3 | 320 | 320 | 320 | 80 |
| A/Tokyo/16161/2016 C3 | 320 | 320 | 80 | 320 |

1. A/Saitama/103/2014 (C3E8) virus is described in footnote of Table 2. Regarding the rest of viruses, C indicates MDCK and/or MDCK-SIAT1 cell-propagated virus and E indicates egg-propagated virus. Number indicates the passage number.
2. Cell-propagated virus.
3. Egg-propagated virus.
4. Homologous titers are underlined.
A(H3N2) Virus without Antigenic Changes in Eggs

Table 4. Antigenicity of egg-adapted influenza A/Saitama/103/2014 (H3N2)

| Virus                | Passage history | Microneutralization titer using post-infection ferret antisera against: |
|----------------------|-----------------|------------------------------------------------------------------------|
|                      |                 | A/Saitama/103/2014 | A/Hong Kong/4801/2014 |
|                      |                 | Cell | Cell | Egg |
| A/Saitama/103/2014   | C3              | 1,280 | 640 | 1,280 |
| C3E8-m2              |                 | 640  | 640 | 320  |
| C3E8-m7              |                 | 640  | 80 | 160  |
| A/Hong Kong/4801/2014| C7              | 2,560 | 2,560 | 2,560 |
|                      | E9              | 640  | 1,280 | 1,280 |

1) NIID-MDCK cell-grown (C3) A/Saitama/103/2014 virus was passaged 4 times in the amniotic cavities and then 4 times in the allantoic cavities (C3E8) of eggs. Cloned viruses (C3E8-m2 and C3E8-m7) were obtained by limiting dilution in the allantoic cavities. A/Hong Kong/4801/2014 virus was propagated in MDCK cells (C7) or eggs (E9).

DISCUSSION

Several amino acid substitutions associated with egg adaptation of A(H3N2) viruses have been reported (14–17); however, almost all of these substitutions are located in the head region of HA, including receptor-binding and antigenic sites, and this situation resulted in antigenic changes. Here, we obtained an egg-adapted Saitama virus possessing a single substitution (H435L; in the stem region of HA), that does not affect HA antigenicity and multiple substitutions in NA (Tables 2 and 3).

Egg-adapted clones C3E8-m2 and C3E8-m7 possess 2 (N329T and T369K) and 7 (V143E, R150H, S331G, S335G, H347R, N358G, and N367D) substitutions, respectively, in addition to T148I and T153N in their NA. Because three of these positions (146–148, 329–331, and 367–369) in NA are a part of potential N-glycosylation sites, and both clones have substitutions at these 3 sites, these substitutions may result in the loss of glycosylation on NA for both viruses. This finding thus suggests that a loss of NA glycosylation may be important for viral adaptation in eggs.

Recent A(H3N2) viruses with the NA D151G substitution have been shown to bind to avian α2-3-linked receptors, and this binding by NA may contribute to virus entry (18,19). Similarly, the NA T148I substitution has been suggested to confer receptor-binding activity to NA (10), perhaps via α2-3-linked receptors. Thus, it is possible that the T148I substitution in NA plays the role of a trigger inducing other substitutions in NA in eggs, where many α2-3-linked receptors are expressed, rather than inducing substitutions in HA. Given that the egg-adapted C3E8-m2 virus replicated well in eggs without any substitutions in the head of HA, the 4 substitutions (T148I, T153N, N329T, and T369K) in NA may be sufficient to confer adequate receptor-binding activity to NA for efficient replication in eggs. Studies designed to test this concept are now underway. It has been reported that the NA T148I substitution arises during virus amplification in cell culture (11). Our results also suggest that it is possible to obtain a virus that does not acquire substitutions at an antigenic site and/or the receptor-binding site of its HA by our procedure, that is, passages in cells followed by passages in eggs, and that this approach may become a solution to the problem of egg-adapted antigenic changes in H3N2 viruses.

The NA substitutions in the egg-adapted C3E8-m2 virus did not strongly affect viral antigenicity when tested with ferret antisera raised against the Saitama and Hong Kong viruses (Table 4), even though the amino acid residues at positions 329 and 369 are known NA antigenic sites (20,21). Although the roles of these 2 NA substitutions in egg adaptation of the A(H3N2) virus remain unclear, our observations suggest that the egg-adapted Saitama virus may be a useful tool for improving our understanding of the egg adaptation mechanisms of recent A(H3N2) viruses.

In summary, we isolated an egg-adapted influenza A(H3N2) strain, A/Saitama/103/2014, which has no amino acid substitutions at the antigenic sites of its HA, resulting in the absence of important antigenic changes even after egg passages. Our results suggest that our strategy may facilitate the production of egg-based vaccine viruses without antigenic alterations.
Acknowledgments We thank Miki Akimoto, Rie Ogawa, Hideaka Miura, Hiromi Sugawara, Aya Sato, and Kayo Watanabe for technical assistance and Susan Watson for scientific editing. We also thank Mayranya Eichelberger for generating A/Saitama/103/2014 (CEXP002) virus. In addition, we thank the Influenza Virus Surveillance Group of Japan for providing the Japanese isolates. This work was supported by a Grant-in-Aid for Emerging and Re-emerging Infectious Diseases from the Ministry of Health, Labour and Welfare, Japan, and by Leading Advanced Projects for Medical Innovation (LEAP) from the Japan Agency for Medical Research and Development (AMED), Japan.

Conflict of interest None to declare.

REFERENCES

1. Katz JM, Wang M, Webster RG. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol. 1990;64:1808-11.

2. Katz JM, Webster RG. Amino acid sequence identity between the HA1 of influenza A(H3N2) viruses grown in mammalian and primary chick kidney cells. J Gen Virol. 1992;73:1159-65.

3. Meyer WJ, Wood JM, Major D, et al. Influence of host cell-mediated variation on the international surveillance of influenza A(H3N2) viruses. Virology. 1993;196:130-7.

4. Rocha EP, Xu X, Hall HE, et al. Comparison of 10 influenza A(H1N1 and H3N2) hemagglutinin sequences obtained directly from clinical specimens to those of MDCK cell- and egg-grown viruses. J Gen Virol. 1993;74:2513-8.

5. Wu NC, Zost SJ, Thompson AJ, et al. A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog. 2017;13:e1006682.

6. Zost SJ, Parkhouse K, Gumina ME, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci USA. 2017;114:12578-83.

7. WHO. Influenza A(H3N2) egg-derived candidate vaccine viruses for development and production of vaccines for use in the 2017–2018 northern hemisphere influenza season. Available at <http://www.who.int/influenza/vaccines/virus/candidates_reagents/summary_a_3n2_egg_v1718.pdf>; Accessed December 7, 2017.

8. Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol. 2003;77:8418-25.

9. Suzuki Y, Odagiri T, Tashiro M, et al. Development of an influenza A master virus for generating high-growth reassortants for A/Anhui/1/2013(H7N9) vaccine production in qualified MDCK cells. PLoS One. 2016;11:e0160040.

10. Takashita E, Ejima M, Ogawa R, et al. Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res. 2016;132:170-7.

11. WHO. Serological diagnosis of influenza by microneutralization assay. Available at <http://www.who.int/influenza/vaccines/laboratory/2010_12_06_serological_diagnosis_of_influenza_by_microneutralization_assay.pdf>; Accessed December 7, 2017.

12. Mohr PG, Deng YM, McKimm-Breschkin JL. The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virol J. 2015;12:67.

13. Tamura D, Nguyen HT, Gleeman K, et al. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrobial Agents Chemother. 2013;57:6141-6.

14. Chen Z, Zhou H, Jin H. The impact of key amino acid substitutions in the hemagglutinin of influenza A(H3N2) viruses on vaccine production and antibody response. Vaccine. 2010;28:4079-85.

15. Lu B, Zhou H, Chan W, et al. Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs. Vaccine. 2006;24:6691-3.

16. Lu B, Zhou H, Ye D, et al. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J Virol. 2005;79:6763-71.

17. Widjaja L, Ilyushina N, Webster RG, et al. Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology. 2006;350:137-45.

18. Gulati S, Smith DF, Cummings RD, et al. Human H3N2 influenza viruses isolated from 1968 to 2012 show varying preference for receptor substructures with no apparent consequences for disease or spread. PLoS One. 2013;8:e66325.

19. Zhu X, McBride R, Nycholat CM, et al. Influenza virus neuraminidases with reduced enzymatic activity that avidly bind sialic acid receptors. J Virol. 2012;86:13371-83.

20. Air GM, Els MC, Brown LE, et al. Location of antigenic sites on the three-dimensional structure of the influenza N2 virus neuraminidase. Virology. 1985;145:237-48.

21. Webster RG, Air GM, Metzger DW, et al. Antigenic structure and variation in an influenza virus N9 neuraminidase. J Virol. 1987;61:2910-6.